Loading
Nanoplatforms for Cancer Theranostics / Photodynamic Therapy Research Studies / Photoacoustic and Ultrasonic Imaging · Journal article
Acs Applied Materials & Interfaces · September 8, 2026
Raises a question worth testing. It does not answer one.
This is a rational design paper describing a novel NIR-II-conjugated polymer nanoparticle (PMH) engineered with tumor microenvironment-responsive elements for dual imaging and combination therapy. The work demonstrates proof-of-concept through in vitro characterization and in vivo imaging in a murine tumor model, with reported imaging intensity approximately seven times background at the tumor site, but provides no comparative efficacy data, survival curves, or clinically relevant disease outcomes.
Preclinical nanoparticle design and characterization study with in vitro and in vivo imaging validation. Murine tumor xenograft model; specific tumor cell line, animal strain, age, and number not reported. In vitro studies used unspecified cell culture systems.. Intervention: PMH nanoagent (P2 conjugated polymer combined with MnO2 and hyaluronic acid-linked BFVPBT connected via disulfide bonds) delivered intravenously or via tumor-targeting route..
PMH nanoagent achieved NIR-II photoacoustic and fluorescence imaging with 'always-on' P2 probe and 'turn-on' BFVPBT fluorescence triggered by tumor microenvironment factors (HAase, GSH, H2O2). In vivo imaging intensity at tumor site reached approximately seven times background intensity for both 'always-on' NIR-II photoacoustic/fluorescence and 'turn-on' fluorescence signals. Nanoagent design combined active tumor targeting via hyaluronic acid with synergistic photodynamic/photothermal/chemodynamic therapy modalities.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a preclinical materials science study reporting rational design and in vitro/in vivo characterization of a nanoagent; it raises mechanistic questions about nanoparticle performance but does not test efficacy against a comparator in any clinical or disease model.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Exploration of precise cancer therapy promotes the development of tumor microenvironment (TME)-responsive imaging-guided phototheranostic nanoagents. Currently, near-infrared-II (NIR-II, 1000−1700 nm) phototheranostic nanoagents are highly desired for deep and high-fidelity imaging. Besides, nontumor-specific imaging and some inherent physiological conditions in TME have severely hindered the enhancement of therapeutic efficacy. Herein, two amphiphilic conjugated polymers (CPs), P1 and P2, were designed with the backbone containing electron-deficient diketopyrrolopyrrole (DPP) as the acceptor (A) and doped electron-rich fluorene as the donor (D). As the doping ratio of fluorene was tuned from 0 to 0.2, P2 was obtained as an “always-on” probe with excellent NIR-II photoacoustic/fluorescence imaging (PAI/FLI) capability as well as photodynamic/photothermal therapy (PDT/PTT) efficacy. Then, a smart phototheranostic nanoagent P2@MnO2@HA-SS-BFVPBT (PMH) based on the combination of “always-on” and “turn-on” probes was rationally designed for dual-FL/PA imaging-guided synergistic PDT/PTT/chemodynamic therapy (CDT). In PMH, the fluorescence of BFVPBT, a conjugated oligomer linked to the side chains of hyaluronic acid (HA) by cystamine containing disulfide (−SS−) bonds, was quenched by MnO2 via an inner filter effect. After the tumor-targeting delivery of PMH via HA, the degradation of HA-SS-BFVPBT and MnO2 was triggered by overexpressed hyaluronidase (HAase), glutathione (GSH), and H2O2 in TME, leading to the “turn-on” BFVPBT fluorescence and the generation of in situ O2 and Mn2+ along with the consumption of GSH, and thereby synergistically enhancing the efficacy of PDT and Fenton-like reaction-mediated CDT by modulating TME. Moreover, the “always-on” NIR-II photoacoustic/fluorescence intensity and the “turn-on” fluorescence intensity at the tumor site can reach up to about seven times the background intensity, achieving effective dynamic monitoring of the nanoagent distribution in vivo. Thus, this smart nanoagent simultaneously combined active tumor targeting and TME response for highly tumor-specific multimodal imaging-guided synergistic PDT/PTT/CDT, providing a simple and universal strategy for enhancing the precision and efficiency of phototheranostics.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.